+ Watch UNIS
on My Watchlist
Last deal really jumped their price, but this price will fall back to earth for several reason
Nice pop 12/2/13 on Novartis deal. Novartis is a big time partner for Unilife. However, the deal was for medicine delivery, Previous recent deals with Hikma and Sanofi could actually be bigger. All are low cost, low volume syringe deals. In the case of Norvartis, it's for an early trial, which is low volume and far from an endpoint. Credibility for the company yes. Overall, may be one to watch, but short term, revenue will not meet new expectations.
as a doctor the use for these material will increase due to focus on health of employee to deliver drug all injectable medication can end up being given this way
turnaround play but everything is on track
$7.70 or more
Unilife makes a patented prefilled syringe with safety features to eliminate the risk of infection from needlestick injuries. Unilife and Sanofi-Aventis have entered into an exclusive five year agreement for the Unifill ready-to-fill syringes. Sanofi-aventis is developing applications in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines.Unilife is speculative stock with interesting prospects for growth or as a takeover target
Late 2012 through 2013 is the earliest I would expect any significant earnings.
I am shocked at how overvalued this company is. Those of you who invested in this, did you even glance at the financial statements? Please somebody explain to me how a terrible company like this can have such a high valuation.
Has the right managment and the right product to make an inpression on its sector.
Extremely High Price for Book Value
Good spec pick. Looking for a rebound on the price after the recent decline.
New mfg facility coming online in 2011. Safety device gives this syringe product an edge and has regulatory trending toward requiring these safety features in US and Europe.
This is a speculative play that may jump around more than a long-tailed cat in a room full of rocking chairs.Their claim to fame is a pre-filled syringe that is impossible to use a second time. This doesn't sound like much, but it's key to preventing AIDs and hepatitis in 3rd world countries.An exclusive agreement with Sanofi Aventis is the closest thing that you have to a moat here, but that gives them 40% of the pre-filled syringe market.Being first to market with a niche product should allow them to gain more short term market share.The key is how quickly that they can lock up exclusive deals. If they can dry up the market before someone else figures out how to duplicate their product, they'll be sitting pretty.Those of you that like to follow me into the pool should do your own DD because this is a very risky pick.
Just got a major account. Market is supposed to be tremendous for this product.
Unilife has a unique, disruptive technology that (in terms of safety devices) is required for use under US law, and likely to become required by law in the EU and other countries. They have the backing of one of the largest pharmaceutical companies in the world (sanofi-Aventis) and they are just getting started. Manufacturing of their first type of syringe just started this year and they are in the process of securing licensing agreements worldwide. They have numerous other safety syringes in the pipeline.Great company. Necessary product. Zero (or far inferior) competition.
this has buyout written all over it at this price, but i have to wait -- Sanofi figured that too, they have a clause in the contract to match any offer for a few years (and they GAVE them the money to build their plant)
This is so insanely underpriced, along with so much potential, that it's a no-brainer. The recently finalized deal with Sanofi-Aventis only confirms a very bright future for this company and it's ingenious product.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions